IL1A and chronic kidney disease: In the future, it may also be useful to test both the efficacy of canakinumab in patients with end-stage renal disease on dialysis and the efficacy of other anti-inflammatory agents that may be useful in CKD, such as anakinra, an IL-1 receptor antagonist, which can inhibit IL-1β and IL-1α, on which few studies have been conducted [65].